Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended): A method for the treatment of neurodegenerative diseases comprising administering an effective amount of a compound of formula (I) to a human patient in need thereof:



(I)

wherein X represents NH_2, NH-C_{1-3}-alkyl, or N(C_{1-3} alkyl)$_2$;

R_1 is a residue derived from the amino acid Phe which may be optionally substituted with one or more methyl groups or one or more halogen atoms[[,]]; or is a residue derived from the amino acid Ile;

R_2 is a residue derived from one of the amino acids Gly or Ile;

Y_1 and Y_2 independently from each other represent H or (C_{1-3}) alkyl;

or a pharmaceutically acceptable salt thereof.

2. (previously presented): The method according to claim 1, wherein X represents NH-C_{1-3}-alkyl, or N(C_{1-3} alkyl)$_2$.

3. (canceled)

4. (canceled)

5. (previously presented): The method according to claim 1, wherein the neurodegenerative disease is Alzheimer's disease.

6. (previously presented): The method according to claim 1, wherein the neurodegenerative disease is mild cognitive impairment.

7. (previously presented): The method according to claim 1, wherein R_1 is a residue which is derived from one of the amino acids Phe which may optionally be substituted with ~~a~~ one or more methyl groups or one or more halogen atoms.

8. (previously presented) The method according to claim 7, wherein R_1 is a residue which is derived from Phe, which may optionally be substituted with one or more halogen atoms.

9. (previously presented): The method according to claim 1, wherein R_2 is a residue which is derived from the amino acid Gly.

10. (previously presented): The method according to claim 1, wherein the compound of formula (I) is glycyl-L-phenylalanyl-L-prolineamide, N,N-diethyl-isoleucyl-phenylalanyl-L-proline ethylamide, N,N-diethyl-isoleucyl-isoleucyl-prolineamide or a pharmaceutically acceptable salt thereof.

11. (currently amended): A pharmaceutical composition comprising one or more compounds of the following formula (I):



(I)

wherein X represents NH_2, NH-C_{1-3}-alkyl, or N(C_{1-3} alkyl)$_2$;

R_1 is a residue derived from the amino acid Phe which may be optionally substituted with one or more methyl groups or one or more halogen atoms[[,]]; or is a residue derived from the amino acid Ile;

R_2 is a residue derived from one of the amino acids Gly or Ile;

Y_1 and Y_2 independently from each other represent H or (C_{1-3}) alkyl;

and pharmaceutically acceptable excipients.

12. (previously presented): The pharmaceutical composition according to claim 11, wherein X represents NH-C_{1-3}-alkyl, or N(C_{1-3} alkyl)$_2$.

13. (previously presented): The pharmaceutical composition according to claim 11 or 12, wherein R_2 is a residue which is derived from the amino acid Gly.

14. (previously presented): The pharmaceutical composition according to claim 11, wherein the compound of formula (I) is glycyl-L-phenylalanyl-L-prolineamide, N,N-diethyl-isoleucyl-phenylalanyl-L-proline ethylamide, N,N-diethyl-isoleucyl-isoleucyl-prolineamide or a pharmaceutically acceptable salt thereof.

15. (canceled)

16. (previously presented): The method according to claim 1, wherein R_1 is a residue which is derived from Phe which is optionally substituted with one or more one or more methyl groups or one or more halogen atoms, R_2 is a residue derived from the amino acid Gly or Ile, and Y_1 and Y_2 independently from each other represent H or (C_{1-3}) alkyl.

17. (previously presented): The pharmaceutical composition according to claim 11, wherein R_1 is a residue which is derived from Phe which is optionally substituted with one or more methyl groups or one or more halogen atoms, R_2 is a residue derived from the amino acid Gly or Ile, and Y_1 and Y_2 independently from each other represent H or (C_{1-3}) alkyl.